08:00 , Feb 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Tumor necrosis factor receptor superfamily, member 21 (TNFRSF21; DR6); caspase-6 apoptosis-related cysteine peptidase (CASP6; MCH2); amyloid...
07:00 , Aug 4, 2008 |  BC Week In Review  |  Clinical News

Anavex preclinical data

Anavex announced that neuroprotection occurred in mice that received 0.1 mg/kg of ANAVEX 1-41, a tetrahydrofuranic compound that modulates muscarinic and sigma-1 receptors. Data were presented at the International Conference on Alzheimer's Disease in Chicago....
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

Anavex preclinical data

In a mouse model of AD, ANAVEX 1-41 protected against amyloid beta peptide-induced memory deficits. The tetrahydrofuranic compound also blocked the expression of caspase-3 , which AVXL said it involved in apoptosis in the hippocampus....